EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses

Hans C Lee, Jeffrey A Zonder, Madhav V Dhodapkar, Sundar Jagannath, James E Hoffman, Attaya Suvannasankha, Mansi R Shah, Suzanne Lentzsch, Rachid Baz, Joseph J Maly, Swathi Namburi, Matthew J Pianko und 19 weitere

Clinical Lymphoma Myeloma and Leukemia · 2026-02 · 26 (2) · e201-e212.e8

DOI: 10.1016/j.clml.2025.11.004 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-02. Verfasst von Hans C Lee und 30 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: Hans.Lee@scri.com. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSRD VA, Regeneron Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Linvoseltamab, a BCMA × CD3 bispecific antibody, demonstrated durable efficacy and generally manageable safety in patients with relapsed/refractory multiple myeloma (RRMM) in the LINKER-MM1 study (NCT03761108). METHODS: We conducted an updated analysis with a longer median follow-up of 21.3 months for 117 patients from LINKER-MM1 who received linvoseltamab 200 mg, including response data in high-risk subgroups. RESULTS: As of July 23, 2024 (data cutoff), the objective response rate (ORR) was 71% (complete response or better [≥CR], 52%), with median duration of response of 29.4 months. Median progression-free survival was not reached, and median overall survival was 31.4 months. Minimal residual disease negativity (10-5 threshold) was achieved in 94% of evaluable patients with ≥CR. High response rates were observed across subgroups defined by baseline patient characteristics (age and race) and treatment history (eg, penta-refractory status). Response rates and survival outcomes were favorable in patients with markers of high disease burden (elevated % bone marrow plasma cells or soluble BCMA) or difficult-to-treat RRMM (including extramedullary plasmacytoma, International Staging System stage 3, and high-risk cytogenetic status); ORR was ≥50% in all subgroups assessed. The most common treatment-emergent adverse events were cytokine release syndrome (46%; Grade 3, 1%; most events occurred during step-up dosing) and neutropenia (44%; Grade ≥3, 43%). Infections were reported in 75% of patients (Grade ≥3, 48%), with the rate decreasing after 6 months of treatment. CONCLUSIONS: Long-term treatment with linvoseltamab 200 mg provided deep and durable responses, with no new safety signals, and thus represents an effective therapeutic option in RRMM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, BispecificNeoplasm Recurrence, LocalHumansMaleFemaleAgedMiddle AgedFollow-Up StudiesAdultAged, 80 and overTreatment Outcome

Stichwörter der Autor:innen

B-cell maturation antigenBispecific antibodyClinical studyHigh-risk featuresLong-term treatment

Substanzen

Antibodies, Bispecific

Autor:innen und Institutionen

  • The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: Hans.Lee@scri.com.
  • Karmanos Cancer Institute, Detroit, MI.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA.
  • Icahn School of Medicine at Mount Sinai, New York, NY.
  • Department of Medicine, University of Miami Health System, Miami, FL.
  • Department of Medicine, Indiana University Simon Cancer Center and Richard L. Roudebush VAMC, Indianapolis, IN.

Förderung

  • CSRD VA
  • Regeneron Pharmaceuticals

Zitieren

APA

Lee, H. C., Zonder, J. A., Dhodapkar, M. V., Jagannath, S., Hoffman, J. E., Suvannasankha, A., Shah, M. R., Lentzsch, S., Baz, R., Maly, J. J., Namburi, S., Pianko, M. J., Ye, J. C., Wu, K. L., Silbermann, R., Min, C. K., Vekemans, M. C., Munder, M., Byun, J. M., …, & Richter, J. (2026). Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses. Clinical Lymphoma Myeloma and Leukemia, 26(2), e201-e212.e8. https://doi.org/10.1016/j.clml.2025.11.004

Vancouver

Lee HC, Zonder JA, Dhodapkar MV, Jagannath S, Hoffman JE, Suvannasankha A, et al. Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses. Clinical Lymphoma Myeloma and Leukemia. 2026;26(2):e201-e212.e8. doi:10.1016/j.clml.2025.11.004

BibTeX
@article{Lee2026,
  author = {Lee, Hans C and Zonder, Jeffrey A and Dhodapkar, Madhav V and Jagannath, Sundar and Hoffman, James E and Suvannasankha, Attaya and Shah, Mansi R and Lentzsch, Suzanne and Baz, Rachid and Maly, Joseph J and Namburi, Swathi and Pianko, Matthew J and Ye, Jing Christine and Wu, Ka Lung and Silbermann, Rebecca and Min, Chang-Ki and Vekemans, Marie-Christiane and Munder, Markus and Byun, Ja Min and Martínez-Lopez, Joaquín and DeVeaux, Michelle and Roccia, Tito and Chokshi, Dhruti and Seraphin, Megan and Knorr, Kate and Boyapati, Anita and Hazra, Anasuya and Rodriguez Lorenc, Karen and Kroog, Glenn S and Bumma, Naresh and Richter, Joshua},
  title = {Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {2},
  pages = {e201--e212.e8},
  doi = {10.1016/j.clml.2025.11.004}
}
Kostenlos starten →